Should You Buy Gilead Sciences Inc (GILD) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
139.720
1 Day change
-0.89%
52 Week Range
141.710
Analysis Updated At
2026/01/28
Buy for a long-term beginner investor. GILD is in a strong uptrend with broad Wall Street support (multiple Buy ratings and rising price targets into earnings). While the stock is technically overbought near resistance and earnings (2026-02-05) can be a near-term catalyst, the underlying fundamentals and pipeline/launch setup support owning it now rather than waiting for a “perfect” dip. A practical approach is to buy now and keep additional cash available in case of a post-earnings pullback.
Technical Analysis
Trend: Bullish. Moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), confirming an uptrend.
Momentum: MACD histogram is positive (1.969) but contracting, implying upside momentum is still present but cooling.
Overbought: RSI_6 is very elevated (~79.9), which often coincides with near-term consolidation or a pullback even in strong uptrends.
Levels: Current price ~139.71 is above R1 (139.118) and approaching R2 (144.019). If price consolidates, the pivot area (~131.186) is a key reference support.
Probability/Pattern read: Similar-pattern model suggests positive bias over 1 week (+3.96%) and 1 month (+17.78%), supportive for a long-term buy despite near-term stretch.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bullish-leaning positioning (both open-interest and volume put/call ratios below 1.0 indicate more call interest than put interest).
Pricing of risk: 30D IV (~30.49) is above historical volatility (~25.14), suggesting the options market is pricing a larger-than-normal move (consistent with the upcoming earnings event).
Flow/participation: Today’s option volume is ~54% of the 30-day average, indicating sentiment is positive but not showing unusually heavy participation on this snapshot.
Technical Summary
Sell
6
Buy
9
Positive Catalysts
1) Clinical/data catalyst: ASCENT-04 showed Trodelvy + Keytruda reduced risk of progression/death by 35% in PD-L1+ metastatic TNBC (supports oncology growth narrative).
2) Analyst support: Multiple firms raised targets and reiterated/initiated Buy ratings in January 2026, citing HIV PrEP (Yeztugo) and upcoming launches/expansions.
3) Earnings catalyst: QDEC 2025 earnings on 2026-02-05 (AH) could validate the growth/launch outlook if guidance and pipeline commentary are constructive.
Neutral/Negative Catalysts
1) Policy headline risk: Medicare drug price negotiations expanded to Part B (office-administered drugs), increasing sector-wide pricing overhang into 2028 implementation timelines.
2) Technical setup: RSI is very high and price is near resistance (around 144), making near-term pullbacks more likely even if the long-term trend remains bullish.
3) Insider activity: Insiders are net sellers recently (selling up ~1259.86% over the last month), which can dampen near-term sentiment.
Financial Performance
Latest reported quarter: 2025/Q3.
Growth trends: Revenue rose to ~$7.77B (+2.97% YoY), indicating steady top-line growth. Profitability surged with Net Income ~$3.05B (+143.58% YoY) and EPS 2.43 (+143.00% YoY), showing strong earnings leverage versus modest revenue growth. Gross margin improved to ~79.8% (+0.83% YoY), supporting quality/defensiveness for long-term investors.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Clearly improving. From late 2025 through January 2026, several major firms raised price targets and reiterated Buy/Overweight views (UBS upgrade to Buy; Citi, Truist, BofA, Morgan Stanley raising targets). Current published targets in the feed cluster roughly in the mid-$140s to mid-$150s (e.g., ~$145–$156), implying upside from ~139.7.
Wall Street pros: Durable HIV franchise, expected PrEP growth (Yeztugo), multiple launch/label expansion catalysts, and oncology optionality (Trodelvy/anito-cel) with improving policy overhang narrative.
Wall Street cons: Potentially conservative guidance after a rally, and ongoing policy/pricing negotiation risk.
Influential trading check: No recent Congress trading data available. Hedge funds: Neutral. Insiders: Selling increased sharply recently.
Wall Street analysts forecast GILD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105 USD and a high forecast of 154 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast GILD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105 USD and a high forecast of 154 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 140.970
Low
105
Averages
137.88
High
154
Current: 140.970
Low
105
Averages
137.88
High
154
Truist
Buy
maintain
$140 -> $145
AI Analysis
2026-01-27
New
Reason
Truist
Price Target
$140 -> $145
AI Analysis
2026-01-27
New
maintain
Buy
Reason
Truist raised the firm's price target on Gilead to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst tells investors in a research note.
Citi
Buy
maintain
$140 -> $156
2026-01-27
New
Reason
Citi
Price Target
$140 -> $156
2026-01-27
New
maintain
Buy
Reason
Citi raised the firm's price target on Gilead to $156 from $140 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD
